Business Context and Reporting Period
This Form 8-K reports on the 2022 Annual Meeting of Stockholders held by BioSig Technologies, Inc. (not Streamex Corp.) on December 20, 2022. The company is incorporated in Delaware and trades on the NASDAQ Capital Market under the symbol BSGM.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
Stockholders voted on four primary proposals. A fifth proposal regarding an equity plan amendment was withdrawn prior to the vote.
- Director Elections: All seven nominees (Kenneth L. Londoner, James J. Barry, David Weild IV, Patrick J. Gallagher, Donald E. Foley, Frederick D. Hrkac, and James L. Klein) were elected by a plurality of votes cast.
- Reverse Stock Split: Stockholders approved an amendment to the Certificate of Incorporation authorizing a reverse stock split at a ratio between 1-for-2 and 1-for-10, to be determined by the Board within one year.
- Executive Compensation: The advisory vote on executive compensation was approved.
- Auditor Ratification: The appointment of Marcum LLP as the independent registered public accounting firm for the 2022 fiscal year was ratified.
- Withdrawn Proposal: The proposal to increase the authorized shares under the 2012 Equity Incentive Plan by 3,000,000 shares was withdrawn.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on financial outlook, or specific risk factors beyond the standard disclosure of the reverse stock split authorization. The approval of the reverse stock split indicates a strategic move to adjust the share structure, though the specific ratio remains at the Board's discretion.
Investor Verification Checklist
- Verify the specific reverse stock split ratio once announced by the Board, as the approved range is 1-for-2 to 1-for-10.
- Confirm the effective date of the reverse stock split, which must occur within one year of the December 20, 2022 approval.
- Review the 2022 Proxy Statement (filed November 7, 2022) for details on the withdrawn equity incentive plan amendment.
- Monitor the company's compliance with NASDAQ listing standards, which often necessitates reverse stock splits.